Keyphrases
Cystic Fibrosis
100%
Hereditary Hemorrhagic Telangiectasia
27%
Forced Expiratory Volume in 1 Second (FEV1)
23%
Patient Registry
21%
Pulmonary Arteriovenous Malformation
14%
Pseudomonas Aeruginosa (P. aeruginosa)
11%
Risk Factors
11%
Elexacaftor-tezacaftor-ivacaftor
10%
Israeli
9%
Epistaxis
9%
Israel
9%
Europe
9%
Disease Severity
9%
Propranolol
8%
Pulmonary Outcomes
7%
Clinical Characteristics
7%
Pediatric
7%
Respiratory Symptoms
7%
Allergic Bronchopulmonary Aspergillosis
7%
Lung Disease
7%
Cerebral Arteriovenous Malformation
7%
Bronchopulmonary Dysplasia
7%
Lung Clearance Index
6%
Sputum Culture
6%
COVID-19
6%
Cardiopulmonary Exercise Testing
6%
Pancreatic Insufficient
6%
Lung Function
6%
Pseudomonas Aeruginosa Infection
6%
Mycobacterium Tuberculosis (M. tb)
6%
Palivizumab
5%
Pulmonary Function Test
5%
Face Mask
5%
Spirometry
5%
Bronchoscopy
5%
Residual Function
5%
Hospitalization
5%
Extremely Premature Birth
5%
Symptomatic children
5%
Asthmatic children
5%
Preconception Carrier Screening
5%
Dry Powder Inhaler
5%
Multicenter Cohort Study
5%
Prevalence Characteristics
5%
Medicine and Dentistry
Cystic Fibrosis
79%
Hereditary Hemorrhagic Telangiectasia
25%
Prevalence
19%
Patient Registry
18%
Silo-Filler's Disease
17%
Pediatrics
17%
Pulmonary Arteriovenous Fistula
14%
Pseudomonas aeruginosa
11%
Forced Expiratory Volume
10%
Cohort Analysis
10%
Diseases
10%
Infection
10%
Lung
9%
Prematurity
9%
Ivacaftor
7%
Tezacaftor
7%
Exercise Test
7%
Epistaxis
7%
Asthma
7%
Patient with Cystic Fibrosis
7%
Lung Clearance
6%
Lung Dysplasia
6%
COVID-19
6%
Quality of Life
6%
Body Mass Index
6%
Atypical Mycobacterium
6%
Pseudomonas Infection
6%
Palivizumab
5%
Cross Sectional Study
5%
Bronchoscopy
5%
Sputum Culture
5%
Cerebral Arteriovenous Malformation
5%
Lung Function
5%
Sputum
5%
Nitric Oxide
5%
Antibiotics
5%
Dyspnea
5%
Bronchiolitis
5%
Embolization
5%